Janssen Seeking Medicare Add-On Payments For CAR-T Carvykti, But CMS May Be Skeptical
Executive Summary
J&J will need to convince the Centers for Medicare and Medicaid Services that its treatment is not substantially similar to existing CAR-T’s in order to qualify for supplemental Medicare reimbursement.
You may also be interested in...
When FDA Changes Your Payment Plans
Five sponsors withdrew their applications for new technology add-on payments from CMS – all due to regulatory reasons happening at the US FDA.
Medicare And CAR-Ts: Breyanzi Denied Add-On Payments But Tecartus, Abecma Approved
CMS shows willingness to continue approving new technology add-on payments for CAR-T treatments despite suggestions they are no longer needed.
FDA’s Real-World Evidence Project Finds That Pragmatic Clinical Trials Are Easier To DUPLICATE
Results from the US Food and Drug Administration’s RCT DUPLICATE demonstration are in. The findings both legitimize certain real-world evidence studies and also highlight the challenges involved in using RWE to replicate randomized clinical trials.